Epigral Q1FY27 PAT Jumps 25% to ₹99 Cr; Approves ₹600 Cr Capex for Epoxy Resin & MPP
Epigral Limited reported Q1FY27 PAT of ₹99 crore, a 25% YoY increase, on revenue of ₹709 crore, up 15% YoY. The board approved a ₹600 crore capex for a new Epoxy Resin & Formulations plant (1,25,000 TPA) and a Multi-Purpose Plant, expected to commission by H2FY28. A pilot plant is slated for Q2FY27.
The announcement includes strong financial performance and a substantial capital expenditure for a new business vertical (Epoxy Resin and Formulations) and a Multi-Purpose Plant, which are expected to drive future growth and diversify the company's portfolio.
The company reported significant year-on-year growth in PAT and revenue, alongside a strategic capital expenditure approval for expansion into high-demand segments like Epoxy Resin, indicating positive future prospects.
Epigral Limited announced its unaudited financial results for the quarter ended June 30, 2026 (Q1FY27). The company reported a 25% year-on-year growth in Profit After Tax (PAT), reaching ₹99 crore, up from ₹79 crore in Q1FY26. Quarterly revenue increased by 15% to ₹709 crore, compared to ₹615 crore in the same period last year. The company's EBITDA grew by 10% to ₹179 crore, with an EBITDA margin of 25% and a PAT margin of 14%. Sales volume saw a 5% year-on-year growth, and overall plant utilization remained above 80%.
In a significant strategic move, Epigral's board approved an investment of approximately ₹600 crore for its entry into the Epoxy Resin and Formulations business. This includes setting up a plant with a production capacity of 1,25,000 tonnes per annum (TPA) and establishing a Multi-Purpose Plant (MPP). The company expects both commercial plants to be commissioned in the second half of FY28. This expansion into advanced materials and specialty chemicals is driven by strong demand from sectors like construction, renewable energy, automotive, and electronics. Notably, over 50% of the raw material for the proposed Epoxy Resin project will be sourced internally, as Epichlorohydrin (ECH) and Caustic Soda are already produced at Epigral's Dahej facility. The MPP will focus on manufacturing downstream products for pharmaceutical, agrochemical intermediates, and water treatment chemicals.
A pilot plant facility for both the Epoxy Resin & Formulations and the MPP is also being established, expected to be operational by Q2FY27, to validate product quality and optimize manufacturing processes before commercial-scale operations. Maulik Patel, Chairman and Managing Director, commented that despite macroeconomic volatility, the company achieved steady growth by leveraging its diversified product mix. He expressed a positive outlook, supported by India's economic growth, and highlighted that these investments will enhance efficiency by utilizing internal raw materials and cater to both domestic and global demand. The company also reported that its ROCE stood at 16% in Q1FY27 compared to 24% in Q1FY26, and Net Debt/EBITDA was 0.8x as of June 30, 2026.
What to do with a filing like this
Epigral Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Epigral Limited. Read the original for the full detail.